The World Health Organization (WHO) is calling on nations to aggressively accelerate the rollout of latest diagnostic tools to help end TB, aiming to close critical gaps in detection and treatment. Marking World TB Day 2026, the global health body is urging the adoption of point-of-care innovations that bring life-saving diagnosis closer to the patients who need them most, reducing the reliance on centralized laboratories and expensive sample transport.
Tuberculosis remains one of the deadliest infectious diseases globally. According to WHO data, more than 29,000 people fall ill with the preventable and curable disease every day and over 3,300 people die from TB daily. Even as global efforts have saved an estimated 83 million lives since 2000, these gains are currently threatened by cuts in global health funding via WHO.
The new guidelines emphasize a shift toward “near point-of-care” testing—portable, battery-powered devices that can deliver results in less than one hour. These tools are available at less than half the cost of many existing molecular diagnostics, potentially allowing patients to start treatment almost immediately after their visit to a health facility.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, described these tools as “truly transformative,” noting their ability to save lives, curb transmission, and reduce overall healthcare costs. He has called on all countries to scale up access to these innovations to ensure every person with TB can be reached and treated promptly.
Transforming Detection: Point-of-Care and New Sample Methods
A primary hurdle in the fight against tuberculosis has been the difficulty of sample collection and the logistics of transporting those samples to distant labs. To combat this, the WHO now recommends the leverage of tongue swab samples. This is a critical development for adults and adolescents who are unable to produce sputum, a common requirement for traditional TB tests. By enabling these high-risk individuals to be tested for the first time, the health community can identify cases in populations at an increased risk of mortality.
the WHO is promoting a cost-saving “sputum pooling” strategy. In this approach, samples from several individuals are combined and tested together. This method is specifically recommended for regions where resources are exceptionally constrained, as it significantly reduces commodity costs and machine time, leading to faster results for both the patients and the TB programs managing them.
The impact of these diagnostics extends beyond tuberculosis. The WHO notes that these portable devices have the potential to be adapted for testing other diseases, such as HIV, mpox, and HPV. This evolution toward “one-stop-shop” services makes healthcare more patient-centered and equitable, particularly in underserved regions.
Closing the Diagnostic Gap for High-Risk Groups
The strategy to end the epidemic involves a layered approach to testing. This includes scaling up proven solutions such as point-of-care urine tests specifically for people living with HIV, alongside low- or moderate-complexity tests for the general population via WHO publications. By integrating these tools across all levels of the health system, countries can reduce delays in treatment initiation and stop the chain of transmission more effectively.
The Economic and Social Imperative of TB Investment
The fight against TB is not only a medical necessity but a strategic economic choice. Dr. Tereza Kasaeva, Director of WHO’s Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections, stated that investing in TB can generate up to US$ 43 in health and economic returns for every dollar spent. However, achieving these returns requires decisive leadership and rapid implementation of the latest WHO recommendations.
Despite the potential for high returns, global funding for TB research remains insufficient. The annual need for research is estimated at around US$ 5 billion, yet current funding levels fall far below this mark. This gap hinders the development of the next generation of diagnostics, medicines, and vaccines necessary to fully eradicate the disease.
To address this, the WHO has partnered with various stakeholders to launch the TB Vaccine Accelerator Council. This initiative is designed to fast-track the development of new vaccines and ensure equitable access by aligning the priorities of governments, researchers, industry leaders, and funders.
World TB Day 2026: A Call for Community-Led Action
Under the 2026 theme, “Yes! You can end TB: Led by countries, powered by people,” the WHO has outlined five urgent priorities for member states:
- Accelerate Technology Rollout: Rapidly deploy diagnostic technologies that can be used near the point-of-care as part of a comprehensive testing network.
- Strengthen People-Centered Care: Ensure meaningful community leadership and continuous engagement in the delivery of TB services.
- Build Resilient Health Systems: Create infrastructure that can safeguard health security against future shocks.
- Address Social Drivers: Use multisectoral action to tackle the economic and social factors that contribute to the spread of TB.
- Protect Essential Services: Safeguard TB services from being dismantled by global crises or funding constraints.
As the global community marks World TB Day 2026, the emphasis remains on prioritizing TB as a central pillar of universal health coverage and global health security. The transition toward decentralized, affordable, and rapid testing is seen as the most viable path toward ending the epidemic.
Key Takeaways for Global Health Strategy
- Speed of Diagnosis: New point-of-care tests deliver results in under one hour and operate on battery power.
- Accessibility: These new tools cost less than half of existing molecular diagnostics.
- Inclusivity: Tongue swabs allow those unable to produce sputum to be diagnosed for the first time.
- Efficiency: Sputum pooling reduces costs and machine time in resource-constrained settings.
- Economic Value: Every $1 invested in TB is estimated to yield $43 in health and economic returns.
The next phase of the global response will depend on the ability of individual countries to integrate these new diagnostic tools to help end TB into their primary healthcare frameworks. The WHO continues to monitor the implementation of these guidelines and the progress of the TB Vaccine Accelerator Council.
We invite health professionals and policymakers to share their experiences with point-of-care implementation in the comments below.